KRAS and lung carcinoma: Most of these mutations were frequently observed in certain focused pathways, e.g., four genes from the EGFR-RAS-RAF signaling pathway, EGFR, KRAS, HER2, and BRAF, behave in a mutual exclusive fashion in lung cancer [1], [2].